The curative potential of CAR-T cell therapy
Drug Discovery World
AUGUST 30, 2024
Dr Nicholas Siciliano, Co-Founder of Vittoria Biotherapeutics, shares insight on the VIPER-101 trial targeting T-cell lymphoma, the company’s aim to ensure progression free survival and opportunities in this sector. MT: I understand that your lead programme is moving into the clinic, with POC human data expected in 2024. Can you elaborate on the status and the aims of your therapeutic pipeline?
Let's personalize your content